중추 신경계 치료 시장 규모, 점유율, 성장 및 산업 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of central nervous system (CNS) treatment Market

The global central nervous system (CNS) treatment market was valued at USD 126.68 billion in 2025 and is projected to grow to USD 138.66 billion in 2026, reaching USD 236.94 billion by 2034, registering a CAGR of 6.93% during 2026-2034. North America dominated the market in 2025, accounting for 45.70% of the global share, supported by strong regulatory frameworks, high treatment accessibility, and the presence of leading pharmaceutical companies.

The CNS treatment market includes therapies for neurodegenerative diseases, neurovascular disorders, mental health conditions, infectious neurological diseases, and others. Rising prevalence of neurological disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, and multiple sclerosis is significantly contributing to market expansion.

COVID-19 Impact

The COVID-19 pandemic had a negative impact on the CNS treatment market, resulting in a -4.2% decline in 2024. Pharmaceutical companies shifted their R&D focus toward COVID-19 vaccines and therapeutics, causing an estimated USD 115.84 billion sales drop in 2024. However, the market rebounded in 2025 as demand returned to pre-pandemic levels and drug development activities resumed.

Market Drivers

Growing Prevalence of Neurological Disorders

The increasing global burden of neurological diseases is a primary growth driver. In the U.S., around 6 million people live with Alzheimer's disease, and this number is projected to rise significantly in the coming decades. The annual treatment and care costs exceed USD 305 billion, creating strong demand for effective CNS therapeutics.

Additionally, rising cases of multiple sclerosis, Parkinson's disease, epilepsy, and mental health disorders are expanding the patient pool. Growing geriatric populations worldwide further accelerate demand for advanced treatment options.

Promising Pipeline Drugs

Several innovative molecules and biologics in late-stage clinical trials are expected to strengthen the market outlook. Strategic collaborations and licensing agreements between pharmaceutical companies are increasing drug development efficiency and global commercialization opportunities.

Market Restraints

Despite growth prospects, the CNS treatment market faces notable challenges:

• Stringent regulatory approvals
• High R&D costs
• Long clinical development timelines
• Difficulty in crossing the blood-brain barrier
• Adverse drug reactions and safety warnings

For example, in 2025, the U.S. FDA issued safety warnings regarding certain multiple sclerosis drugs, highlighting potential treatment risks. These factors may limit market growth during the forecast period.

Market Segmentation Analysis

By Disease Type

• Neurodegenerative diseases dominated the market with a 47.08% share in 2026, driven by high sales of multiple sclerosis and Alzheimer's drugs.
• Mental health disorders are witnessing rising demand due to increased global awareness and post-pandemic psychological stress.
• Neurovascular and infectious diseases also contribute to steady market growth.

By Drug Class

• Immunomodulators led the market in 2026 with a 52.08% share, supported by innovation in multiple sclerosis therapies.
• Interferons, antidepressants, dopamine agonists, analgesics, and other CNS drugs contribute significantly to overall revenue.

By Drug Type

• Non-biologics dominated the market with a 69.05% share in 2026, owing to easier regulatory approvals and strong prescription rates.
• Biologics are expected to grow steadily due to supportive government initiatives and expanding biologic pipelines.

By Distribution Channel

• Hospital pharmacies held the largest share due to high prescription drug sales and preference for hospital-based treatments.
• Retail pharmacies and online pharmacies are expanding, particularly in emerging markets.

Regional Insights

North America

North America generated USD 57.96 billion in 2025 and USD 63.13 billion in 2026. The U.S. market alone is projected to reach USD 58.25 billion in 2026. Growth is driven by strong R&D infrastructure, high disease prevalence, regulatory support from the FDA, and robust reimbursement systems.

Europe

Europe holds the second-largest market share, supported by favorable reimbursement policies and public healthcare systems such as the NHS. The UK market is projected to reach USD 4.98 billion in 2026, while Germany is projected at USD 7.51 billion in 2026.

Asia Pacific

Asia Pacific is expected to register the highest CAGR due to increasing geriatric populations and improving healthcare infrastructure. The Japan market is projected to reach USD 9.04 billion in 2026, China USD 5.99 billion, and India USD 3.16 billion.

Latin America & Middle East & Africa

These regions are expected to witness moderate growth due to limited product approvals and slower market penetration.

Key Industry Players

Major companies operating in the CNS treatment market include:

• Biogen
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd
• Novartis AG
• Johnson & Johnson Services, Inc.
• Teva Pharmaceutical Industries Ltd.
• Sanofi
• Otsuka Holdings

These companies focus on pipeline expansion, partnerships, regulatory approvals, and geographic expansion to strengthen their market positions.

Conclusion

The global CNS treatment market is poised for steady expansion from USD 126.68 billion in 2025 to USD 236.94 billion by 2034, driven by rising neurological disease prevalence, increasing geriatric population, strong R&D pipelines, and improved treatment accessibility. Although regulatory complexities and high development costs present challenges, continued innovation, strategic partnerships, and expanding healthcare infrastructure are expected to sustain long-term market growth across major regions.

Segmentation By Disease Type

• Neurovascular Diseases
  • Hemorrhagic Stroke
  • Ischemic Stroke
  • Others
• Neurodegenerative Diseases
  • Alzheimer's Disease
  • Parkinson's Disease
  • Multiple Sclerosis
  • Others
• Mental Health
  • Epilepsy
  • Mood Disorders
  • Anxiety Disorders
  • Others
• Infectious Diseases
  • Meningitis
  • Encephalitis
  • Others
• Others

By Drug Class

• Immunomodulatory Drugs
• Interferons
• Decarboxylase Inhibitors
• Dopamine Agonists
• Antidepressants
• Analgesics
• Others

By Drug Type

• Biologics
• Non-biologics

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America (By Disease Type, By Drug Class, By Drug Type By Distribution Channel, and By Country)
  • U.S. (By Drug Type)
  • Canada (By Drug Type)
• Europe (By Disease Type, By Drug Class, By Drug Type, By Distribution Channel, and By Country)
  • U.K. (By Drug Type)
  • Germany (By Drug Type)
  • France (By Drug Type)
  • Italy (By Drug Type)
  • Spain (By Drug Type)
  • Rest of Europe (By Drug Type)
• Asia Pacific (By Disease Type, By Drug Class, By Drug Type, By Distribution Channel, and By Country)
  • China (By Drug Type)
  • Japan (By Drug Type)
  • India (By Drug Type)
  • Australia (By Drug Type)
  • Southeast Asia (By Drug Type)
  • Rest of Asia Pacific (By Drug Type)
• Latin America (By Disease Type, By Drug Class, By Drug Type, By Distribution Channel, and by Country)
  • Brazil (By Drug Type)
  • Mexico (By Drug Type)
  • Rest of Latin America (By Drug Type)
• Middle East & Africa (By Disease Type, By Drug Class, By Drug Type, By Distribution Channel, and by Country)
  • GCC (By Drug Type)
  • South Africa (By Drug Type)
  • Rest of Middle East & Africa (By Drug Type)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities

4. Key Insights

• 4.1. Key Industry Developments- Mergers, Acquisitions and Partnerships
• 4.2. New Product Launches
• 4.3. Pipeline Analysis
• 4.4. Overview of Regulatory Scenario
• 4.5. Impact of COVID-19 on the Market

5. Global Central Nervous System Treatment Market Analysis, Insights and Forecast, 2025-2034

• 5.1. Key Findings / Summary
• 5.2. Market Analysis, Insights and Forecast - By Drug Class
  • 5.2.1. Immunomodulatory Drugs
  • 5.2.2. Interferons
  • 5.2.3. Decarboxylase Inhibitors
  • 5.2.4. Dopamine Agonists
  • 5.2.5. Antidepressants
  • 5.2.6. Analgesics
  • 5.2.7. Others
• 5.3. Market Analysis, Insights and Forecast - By Disease Type
  • 5.3.1. Neurovascular Diseases
    • 5.3.1.1. Hemorrhagic Stroke
    • 5.3.1.2. Ischemic Stroke
    • 5.3.1.3. Others
  • 5.3.2. Neurodegenerative Diseases
    • 5.3.2.1. Alzheimer's Disease
    • 5.3.2.2. Parkinson's Disease
    • 5.3.2.3. Multiple Sclerosis
    • 5.3.2.4. Others
  • 5.3.3. Mental Health
    • 5.3.3.1. Epilepsy
    • 5.3.3.2. Mood Disorders
    • 5.3.3.3. Anxiety Disorders
    • 5.3.3.4. Others
    • 5.3.3.5. Infectious Diseases
    • 5.3.3.6. Meningitis
    • 5.3.3.7. Encephalitis
    • 5.3.3.8. Others
  • 5.3.4. Others
• 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.4.1. Hospital Pharmacy
  • 5.4.2. Retail Pharmacy
  • 5.4.3. Others
• 5.5. Market Analysis, Insights and Forecast - By Drug Type
  • 5.5.1. Biologics
  • 5.5.2. Non-biologics
• 5.6. Market Analysis, Insights and Forecast - By Region
  • 5.6.1. North America
  • 5.6.2. Europe
  • 5.6.3. Asia Pacific
  • 5.6.4. Latin America
  • 5.6.5. Middle East & Africa

6. North America Central Nervous System Treatment Market Analysis, Insights and Forecast, 2025-2034

• 6.1. Key Findings / Summary
• 6.2. Market Analysis, Insights and Forecast - By Drug Class
  • 6.2.1. Immunomodulatory Drugs
  • 6.2.2. Interferons
  • 6.2.3. Decarboxylase Inhibitors
  • 6.2.4. Dopamine Agonists
  • 6.2.5. Antidepressants
  • 6.2.6. Analgesics
  • 6.2.7. Others
• 6.3. Market Analysis, Insights and Forecast - By Disease Type
  • 6.3.1. Neurovascular Diseases
    • 6.3.1.1. Hemorrhagic Stroke
    • 6.3.1.2. Ischemic Stroke
    • 6.3.1.3. Others
  • 6.3.2. Neurodegenerative Diseases
    • 6.3.2.1. Alzheimer's Disease
    • 6.3.2.2. Parkinson's Disease
    • 6.3.2.3. Multiple Sclerosis
    • 6.3.2.4. Others
  • 6.3.3. Mental Health
    • 6.3.3.1. Epilepsy
    • 6.3.3.2. Mood Disorders
    • 6.3.3.3. Anxiety Disorders
    • 6.3.3.4. Others
    • 6.3.3.5. Infectious Diseases
    • 6.3.3.6. Meningitis
    • 6.3.3.7. Encephalitis
    • 6.3.3.8. Others
  • 6.3.4. Others
• 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.4.1. Hospital Pharmacy
  • 6.4.2. Retail Pharmacy
  • 6.4.3. Others
• 6.5. Market Analysis, Insights and Forecast - By Drug Type
  • 6.5.1. Biologics
  • 6.5.2. Non-biologics
• 6.6. Market Analysis, Insights and Forecast - By Country
  • 6.6.1. U.S. (By Drug Type)
  • 6.6.2. Canada (By Drug Type)

7. Europe Central Nervous System Treatment Market Analysis, Insights and Forecast, 2025-2034

• 7.1. Key Findings / Summary
• 7.2. Market Analysis, Insights and Forecast - By Drug Class
  • 7.2.1. Immunomodulatory Drugs
  • 7.2.2. Interferons
  • 7.2.3. Decarboxylase Inhibitors
  • 7.2.4. Dopamine Agonists
  • 7.2.5. Antidepressants
  • 7.2.6. Analgesics
  • 7.2.7. Others
• 7.3. Market Analysis, Insights and Forecast - By Disease Type
  • 7.3.1. Neurovascular Diseases
    • 7.3.1.1. Hemorrhagic Stroke
    • 7.3.1.2. Ischemic Stroke
    • 7.3.1.3. Others
  • 7.3.2. Neurodegenerative Diseases
    • 7.3.2.1. Alzheimer's Disease
    • 7.3.2.2. Parkinson's Disease
    • 7.3.2.3. Multiple Sclerosis
    • 7.3.2.4. Others
  • 7.3.3. Mental Health
    • 7.3.3.1. Epilepsy
    • 7.3.3.2. Mood Disorders
    • 7.3.3.3. Anxiety Disorders
    • 7.3.3.4. Others
    • 7.3.3.5. Infectious Diseases
    • 7.3.3.6. Meningitis
    • 7.3.3.7. Encephalitis
    • 7.3.3.8. Others
  • 7.3.4. Others
• 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.4.1. Hospital Pharmacy
  • 7.4.2. Retail Pharmacy
  • 7.4.3. Others
• 7.5. Market Analysis, Insights and Forecast - By Drug Type
  • 7.5.1. Biologics
  • 7.5.2. Non-biologics
• 7.6. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 7.6.1. U.K. (By Drug Type)
  • 7.6.2. Germany (By Drug Type)
  • 7.6.3. France (By Drug Type)
  • 7.6.4. Spain (By Drug Type)
  • 7.6.5. Italy (By Drug Type)
  • 7.6.6. Scandinavia (By Drug Type)
  • 7.6.7. Rest of Europe (By Drug Type)

8. Asia Pacific Central Nervous System Treatment Market Analysis, Insights and Forecast, 2025-2034

• 8.1. Key Findings / Summary
• 8.2. Market Analysis, Insights and Forecast - By Drug Class
  • 8.2.1. Immunomodulatory Drugs
  • 8.2.2. Interferons
  • 8.2.3. Decarboxylase Inhibitors
  • 8.2.4. Dopamine Agonists
  • 8.2.5. Antidepressants
  • 8.2.6. Analgesics
  • 8.2.7. Others
• 8.3. Market Analysis, Insights and Forecast - By Disease Type
  • 8.3.1. Neurovascular Diseases
    • 8.3.1.1. Hemorrhagic Stroke
    • 8.3.1.2. Ischemic Stroke
    • 8.3.1.3. Others
  • 8.3.2. Neurodegenerative Diseases
    • 8.3.2.1. Alzheimer's Disease
    • 8.3.2.2. Parkinson's Disease
    • 8.3.2.3. Multiple Sclerosis
    • 8.3.2.4. Others
  • 8.3.3. Mental Health
    • 8.3.3.1. Epilepsy
    • 8.3.3.2. Mood Disorders
    • 8.3.3.3. Anxiety Disorders
    • 8.3.3.4. Others
    • 8.3.3.5. Infectious Diseases
    • 8.3.3.6. Meningitis
    • 8.3.3.7. Encephalitis
    • 8.3.3.8. Others
  • 8.3.4. Others
• 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.4.1. Hospital Pharmacy
  • 8.4.2. Retail Pharmacy
  • 8.4.3. Others
• 8.5. Market Analysis, Insights and Forecast - By Drug Type
  • 8.5.1. Biologics
  • 8.5.2. Non-biologics
• 8.6. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 8.6.1. Japan (By Drug Type)
  • 8.6.2. China (By Drug Type)
  • 8.6.3. India (By Drug Type)
  • 8.6.4. Australia (By Drug Type)
  • 8.6.5. Southeast Asia (By Drug Type)
  • 8.6.6. Rest of Asia Pacific (By Drug Type)

9. Latin America Central Nervous System Treatment Market Analysis, Insights and Forecast, 2025-2034

• 9.1. Key Findings / Summary
• 9.2. Market Analysis, Insights and Forecast - By Drug Class
  • 9.2.1. Immunomodulatory Drugs
  • 9.2.2. Interferons
  • 9.2.3. Decarboxylase Inhibitors
  • 9.2.4. Dopamine Agonists
  • 9.2.5. Antidepressants
  • 9.2.6. Analgesics
  • 9.2.7. Others
• 9.3. Market Analysis, Insights and Forecast - By Disease Type
  • 9.3.1. Neurovascular Diseases
    • 9.3.1.1. Hemorrhagic Stroke
    • 9.3.1.2. Ischemic Stroke
    • 9.3.1.3. Others
  • 9.3.2. Neurodegenerative Diseases
    • 9.3.2.1. Alzheimer's Disease
    • 9.3.2.2. Parkinson's Disease
    • 9.3.2.3. Multiple Sclerosis
    • 9.3.2.4. Others
  • 9.3.3. Mental Health
    • 9.3.3.1. Epilepsy
    • 9.3.3.2. Mood Disorders
    • 9.3.3.3. Anxiety Disorders
    • 9.3.3.4. Others
    • 9.3.3.5. Infectious Diseases
    • 9.3.3.6. Meningitis
    • 9.3.3.7. Encephalitis
    • 9.3.3.8. Others
  • 9.3.4. Others
• 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.4.1. Hospital Pharmacy
  • 9.4.2. Retail Pharmacy
  • 9.4.3. Others
• 9.5. Market Analysis, Insights and Forecast - By Drug Type
  • 9.5.1. Biologics
  • 9.5.2. Non-biologics
• 9.6. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 9.6.1. Brazil (By Drug Type)
  • 9.6.2. Mexico (By Drug Type)
  • 9.6.3. Rest of Latin America (By Drug Type)

10. Middle East & Africa Central Nervous System Treatment Market Analysis, Insights and Forecast, 2025-2034

• 10.1. Key Findings / Summary
• 10.2. Market Analysis, Insights and Forecast - By Drug Class
  • 10.2.1. Immunomodulatory Drugs
  • 10.2.2. Interferons
  • 10.2.3. Decarboxylase Inhibitors
  • 10.2.4. Dopamine Agonists
  • 10.2.5. Antidepressants
  • 10.2.6. Analgesics
  • 10.2.7. Others
• 10.3. Market Analysis, Insights and Forecast - By Disease Type
  • 10.3.1. Neurovascular Diseases
    • 10.3.1.1. Hemorrhagic Stroke
    • 10.3.1.2. Ischemic Stroke
    • 10.3.1.3. Others
  • 10.3.2. Neurodegenerative Diseases
    • 10.3.2.1. Alzheimer's Disease
    • 10.3.2.2. Parkinson's Disease
    • 10.3.2.3. Multiple Sclerosis
    • 10.3.2.4. Others
  • 10.3.3. Mental Health
    • 10.3.3.1. Epilepsy
    • 10.3.3.2. Mood Disorders
    • 10.3.3.3. Anxiety Disorders
    • 10.3.3.4. Others
    • 10.3.3.5. Infectious Diseases
    • 10.3.3.6. Meningitis
    • 10.3.3.7. Encephalitis
    • 10.3.3.8. Others
  • 10.3.4. Others
• 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.4.1. Hospital Pharmacy
  • 10.4.2. Retail Pharmacy
  • 10.4.3. Others
• 10.5. Market Analysis, Insights and Forecast - By Drug Type
  • 10.5.1. Biologics
  • 10.5.2. Non-biologics
• 10.6. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 10.6.1. GCC Countries (By Drug Type)
  • 10.6.2. South Africa (By Drug Type)
  • 10.6.3. Rest of Middle East & Africa (By Drug Type)

11. Competitive Analysis

• 11.1. Key Industry Developments
• 11.2. Global Market Share Analysis (2025)
• 11.3. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability))
  • 11.3.1. Biogen
    • 11.3.1.1. Overview,
    • 11.3.1.2. Products,
    • 11.3.1.3. SWOT analysis,
    • 11.3.1.4. Recent developments,
    • 11.3.1.5. strategies,
    • 11.3.1.6. financials (based on availability)
  • 11.3.2. Pfizer, Inc.
    • 11.3.2.1. Overview,
    • 11.3.2.2. Products,
    • 11.3.2.3. SWOT analysis,
    • 11.3.2.4. Recent developments,
    • 11.3.2.5. strategies,
    • 11.3.2.6. financials (based on availability)
  • 11.3.3. F. Hoffmann-La Roche Ltd
    • 11.3.3.1. Overview,
    • 11.3.3.2. Products,
    • 11.3.3.3. SWOT analysis,
    • 11.3.3.4. Recent developments,
    • 11.3.3.5. strategies,
    • 11.3.3.6. financials (based on availability)
  • 11.3.4. Novartis AG
    • 11.3.4.1. Overview,
    • 11.3.4.2. Products,
    • 11.3.4.3. SWOT analysis,
    • 11.3.4.4. Recent developments,
    • 11.3.4.5. strategies,
    • 11.3.4.6. financials (based on availability)
  • 11.3.5. Johnson and Johnson Services Inc.
    • 11.3.5.1. Overview,
    • 11.3.5.2. Products,
    • 11.3.5.3. SWOT analysis,
    • 11.3.5.4. Recent developments,
    • 11.3.5.5. strategies,
    • 11.3.5.6. financials (based on availability)
  • 11.3.6. Teva Pharmaceutical Industries Lt
    • 11.3.6.1. Overview,
    • 11.3.6.2. Products,
    • 11.3.6.3. SWOT analysis,
    • 11.3.6.4. Recent developments,
    • 11.3.6.5. strategies,
    • 11.3.6.6. financials (based on availability)
  • 11.3.7. Sanofi
    • 11.3.7.1. Overview,
    • 11.3.7.2. Products,
    • 11.3.7.3. SWOT analysis,
    • 11.3.7.4. Recent developments,
    • 11.3.7.5. strategies,
    • 11.3.7.6. financials (based on availability)
  • 11.3.8. Otsuka Holdings
    • 11.3.8.1. Overview,
    • 11.3.8.2. Products,
    • 11.3.8.3. SWOT analysis,
    • 11.3.8.4. Recent developments,
    • 11.3.8.5. strategies,
    • 11.3.8.6. financials (based on availability)
  • 11.3.9. Other Prominent Players
    • 11.3.9.1. Overview,
    • 11.3.9.2. Products,
    • 11.3.9.3. SWOT analysis,
    • 11.3.9.4. Recent developments,
    • 11.3.9.5. strategies,
    • 11.3.9.6. financials (based on availability)